The J&J opioid case in Oklahoma darkens the outlook for other drug companies

first_img Ed Silverman The J&J opioid case in Oklahoma darkens the outlook for other drug companies By Ed Silverman Aug. 27, 2019 Reprints Patrick Sison/AP STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+. First 30 days free. GET STARTED Log In | Learn More Now that an Oklahoma state court judge has ruled Johnson & Johnson (JNJ) must pay $572 million to the state for contributing to the opioid crisis there, Wall Street is engaged in a parlor game seeking to answer a key question: How will this decision affect the massive amount of litigation elsewhere?Sorting this out takes us in a number of directions because there are lawsuits filed against different drug makers in different states, along with a huge case consolidated in a federal court in Cleveland. There are also varying legal issues in play, increasing pressure to reach settlements, and uncertainty about the extent to which drug companies have the ability to reach any number of deals. About the Author Reprints What’s included?center_img [email protected] Pharmalot GET STARTED @Pharmalot Tags legalopioidspharmaceuticalsSTAT+states Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. What is it? Pharmalot Columnist, Senior Writer Ed covers the pharmaceutical industry.last_img

Leave a Comment

Your email address will not be published. Required fields are marked *